The Use of Immunoglobulin Therapy for Patients With Primary Immune Deficiency: An Evidence-Based Practice Guideline
To access this article, please choose from the options below
STATEMENT OF CONFLICT OF INTEREST: Dr Richard Warrington has received funding from Bayer Canada and from Baxter Canada. Dr Bruce Mazer has received research funding from the Bayer/Talecris Canadian Blood Services/Hema-Quebec Partnership Fund since 1995. He has received additional research funding from Bayer and Talecris. His department has received unrestricted educational grants from Bayer and CSL Behring. Dr Elie Haddad has received research funding from the Bayer/Talecris Canadian Blood Services/Hema-Quebec Partnership Fund since 2007. His department has received unrestricted educational grants from Bayer-Talecris and Baxter. He is an advisory board member for CSL Behring and Bristoll Myers Squibb. He has also received honoraria from Talecris, Novartis, and Baxter. Dr Bob Schellenberg is an advisory board member for CSL Behring and in previous years Bayer and Baxter. He is a recipient of a Grant-in-Aid from Bayer (now Talecris). Dr Nadine Shehata is an employee of Canadian Blood Services, as was Dr Heather Hume during the period of the development of these guidelines.
Funding was provided from an unrestricted education grant from Bayer, Inc, to Canadian Blood Services. Bayer did not have any role in the selection of panel members, the literature search, the selection of articles, or in the development of the recommendations.
PII: S0887-7963(09)00091-1
doi:10.1016/j.tmrv.2009.09.011
© 2010 Elsevier Inc. All rights reserved.
